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Background-—Prehypertension is associated with higher cardiovascular risk, target organ damage, and incidence of hypertension.
The Prevention of Hypertension in Patients with PreHypertension (PREVER-Prevention) trial aimed to evaluate the efficacy and
safety of a low-dose diuretic for the prevention of hypertension and end-organ damage.
Methods and Results-—This randomized, parallel, double-blind, placebo-controlled trial was conducted in21Brazilian academicmedical
centers. Participantswithprehypertensionwhowereaged30 to70 years andwhodid not reachoptimal bloodpressureafter 3 monthsof
lifestyle intervention were randomized to a chlorthalidone/amiloride combination pill or placebo and were evaluated every 3 months
during 18 months of treatment. The primary outcome was incidence of hypertension. Development or worsening of microalbuminuria,
new-onset diabetes mellitus, and reduction of left ventricular mass were secondary outcomes. Participant characteristics were evenly
distributed by trial arms. The incidence of hypertension was significantly lower in 372 study participants allocated to diuretics compared
with358allocated toplacebo (hazard ratio 0.56, 95%CI 0.38–0.82), resulting in a cumulative incidenceof11.7% in thediuretic armversus
19.5% in the placebo arm (P=0.004). Adverse events; levels of blood glucose, glycosylated hemoglobin, creatinine, andmicroalbuminuria;
and incidence of diabetes mellitus were no different between the 2 arms. Left ventricular mass assessed through Sokolow-Lyon voltage
and voltage-duration product decreased to a greater extent in participants allocated to diuretic therapy comparedwith placebo (P=0.02).
Conclusions-—A combination of low-dose chlorthalidone and amiloride effectively reduces the risk of incident hypertension and
beneficially affects left ventricular mass in patients with prehypertension.
Clinical Trial Registration-—URL: http://www.ClinicalTrials.gov, www.ensaiosclinicos.gov. Unique identifiers: NCT00970931,
RBR-74rr6s. ( J Am Heart Assoc. 2016;5:e004248 doi: 10.1161/JAHA.116.004248)
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P rehypertension (systolic blood pressure [BP] 120–139 ordiastolic BP 80–89 mm Hg) conveys 3 potentially dele-
terious consequences. First, it substantially increases the risk
of developing hypertension.1,2 In a Brazilian cohort study, 4 of
every 5 adults aged 40 to 49 years who had prehypertension
were destined to develop hypertension during 10 years of
follow-up.1 Second, patients with prehypertension already
have evidence of left ventricular geometric and functional
abnormalities3 and are at higher risk of developing left
ventricular hypertrophy.4 Third, cohort experience provides
abundant evidence that, compared with their counterparts
with optimal or normal BP levels, adults with prehypertension
are at a substantially higher risk of cardiovascular mortality.5
For these reasons, interventions aimed at lowering BP and
preventing cardiovascular disease (CVD) events, target organ
damage, and progression to hypertension would seem to be
highly desirable for patients with prehypertension.
Clinical trials have already documented the effectiveness
of antihypertensive drug therapy in secondary prevention of
CVD events in adults with prehypertension.6 The magnitude of
the prevention benefits identified in these trials has been
consistent with projections from cohort study experience.7
Nevertheless, no clinical trial evidence exists to document
prevention of CVD events following BP lowering in patients
with prehypertension but no history of a clinical CVD event.
Given the low absolute risk of a clinical CVD outcome in
adults with uncomplicated prehypertension, an event-based
trial of antihypertensive treatment in this setting would
require a prohibitively large sample size to detect an
intervention benefit. Prevention of incident hypertension has
already been demonstrated with nonpharmacological8 and
drug treatments9,10 in patients with prehypertension; how-
ever, long-term maintenance of nonpharmacological interven-
tions is difficult.11 The 2 drug-treatment trials had design
limitations,9–12 studied only patients at the upper limit of
prehypertension, and failed to study the effect of treatment
on target organ damage.
Our trial was designed to investigate the effectiveness and
safety of low-dose diuretic therapy for prevention of hyper-
tension and reduction of target organ damage in adults with
prehypertension.
Methods
Study Design
Prevention of Hypertension in Patients with PreHypertension
(PREVER-Prevention) was a randomized (concealed), placebo-
controlled, double-blind, clinical trial conducted at 21 aca-
demic medical centers in Brazil. The study was approved by
the ethics committee of the Hospital de Clinicas de Porto
Alegre, which is accredited by the Office of Human Research
Protections as an institutional review board and by the ethics
committee at each medical center. All participants signed an
informed consent form prior to participation in the trial. This
study was registered at ClinicalTrials.gov (NCT00970931) and
ReBEC (Registro Brasileiro de Ensaios Clinicos), and its
detailed rationale and methods have been published else-
where.13
Participants
Participants were eligible if they were aged 30 to 70 years,
had systolic BP between 120 and 139 mm Hg or diastolic BP
between 80 and 89 mm Hg, and were not taking antihyper-
tensive medication. Exclusion criteria included low life
expectancy, previous CVD, other indications for the use of a
diuretic, study drug intolerance, or pregnancy. Prior to
randomization, all study participants were enrolled in a 3-
month lifestyle-intervention phase that provided counseling
aimed at weight loss, reduction in dietary sodium intake,
consumption of a DASH (Dietary Approaches to Stop
Hypertension)–type diet, and increased physical activity.
Participants whose average BP was still within the prehyper-
tension range after 3 months of lifestyle intervention were
randomized to 1 of the 2 treatment groups.
Randomization and Masking
Randomization was performed centrally using a Web-based
automated system available on the study’s website, with
permuted block sizes of 4, 6, 8, or 10, stratified by center. The
randomization sequence was generated at the data center
using alphanumeric codes and implemented by the study’s
website independent of the team that enrolled participants and
assigned them to the trial groups. After assignment to
intervention groups, participants, care providers, and those
assessing outcomes remained blinded until the end of the trial.
Interventions
Participants were randomly assigned to receive either a
combination pill with chlorthalidone 12.5 mg plus amiloride
2.5 mg (chlorthalidone/amiloride) or placebo at a 1:1 ratio. In
the PREVER-Prevention trial, BP-lowering medication was not
changed during the experimental phase. Chlorthalidone was
chosen because it was widely tested in previous randomized
clinical trials and has a longer half-life and greater capacity
to lower BP compared with thiazide diuretics such as
hydrochlorothiazide.14 The main adverse effect of chlorthali-
done, hypokalemia, can be minimized or avoided by concur-
rent use of a potassium-sparing agent, such as amiloride.15
The active and placebo pills were prepared in a certified
pharmaceutical laboratory. The study drugs were identical in
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size, shape, color, taste, and texture. Follow-up visits were
conducted at 3, 6, 9, 12, 15, and 18 months following
randomization. Additional visits could be scheduled to assess
intercurrent illnesses or adverse effects. Adherence to the
treatment was evaluated by self-report and by pill counting.
Outcomes
The primary outcome was incidence of hypertension. Partic-
ipants with an average of 2 BP measurements ≥140 for
systolic BP or ≥90 mm Hg for diastolic BP at the follow-up
visits were scheduled for 2 additional BP measurements at a
confirmatory visit. Hypertension was diagnosed if the average
of all 4 BP measurements was ≥140 mm Hg for systolic BP or
≥90 mm Hg for diastolic BP, according to standardized
recommendations.16,17 Self-reported adverse events, devel-
opment or worsening of microalbuminuria, changes in left
ventricular mass (LVM), and fatal or nonfatal major CVD
events were secondary outcomes. Laboratory measurements
of fasting plasma glucose, glycosylated hemoglobin, lipid
levels, serum electrolyte and uric acid levels, urinary microal-
buminuria levels, and 12-lead ECGs were obtained at baseline
and at the 18-month visit. All measurements were performed
using standardized protocols in core laboratories. Diabetes
mellitus was diagnosed when glycosylated hemoglobin was
≥6.5% or plasma fasting glucose was ≥126 mg/dL (7.0 mmol/
L). BP was measured twice according to guideline recommen-
dations at 3 clinic visits with a validated automatic electronic
device (Microlife BP 3BTO-A; Micromed Biotecnologia Ltda), that
captures systolic and diastolic BP by automatically recognizing
the beginning and end of cuff oscillation. The average of 6 BP
measurements was used to characterize systolic and diastolic
BP at baseline and at the end of the trial. Microalbuminuria was
determined at the core laboratory by nephelometry. Measure-
ment of LVM was based on ECG recordings using Sokolow-Lyon
and Cornell voltage and voltage-duration products.18,19 Three
experienced cardiologists who were blinded to treatment
allocation used a semiautomated method to perform the
analyses in the ECG core laboratory. Replication of their
findings was confirmed by means of a standardized assessment
in a subsample. Adverse events were ascertained by self-report
of symptoms and responses to a semistructured questionnaire.
A committee blinded to treatment assignment adjudicated
potential CVD event outcome reports using standardized
definitions and procedures.
Quality Control
All study investigators and research staff members were
trained and certified in the methods used to implement our
trial protocol during regional and individual center meetings.
Study data were collected locally using a Web-based system,
with central monitoring of the variables collected, periodic
reports for review by the participating centers, and a direct
check of 15% to 20% of the records in every center. Study
performance was monitored electronically, and inconsisten-
cies in the database were reviewed and resolved in a prompt
fashion. Monitoring visits onsite were conducted at each
center a minimum of 3 times by a study coordinator and twice
by the 2 principal investigators (S.C.F. and F.D.F.). Laboratory
quality control was supervised by the central laboratory
according to standard procedures.
Sample Size
A sample size of 568 participants per group was originally
planned with the expectation that this number would provide
85% power to detect a 40% reduction in the incidence of
hypertension for participants in the chlorthalidone/amiloride
group, assuming a cumulative incidence rate of 14% in the
placebo group, with 2-sided a=0.05. The sample size was
rounded to 625 per group to compensate for losses during
follow-up.
Statistical Analysis
Trial results were analyzed using the intention-to-treat
approach. The proportional hazards model for interval-
censored failure time data was used to test for statistical
significance between the 2 treatment arms and to calculate
the hazard ratio and 95% CIs as a measure of the risk of
developing hypertension. Plots were used to display the
density incidence of hypertension by treatment groups over
time. The assumption of proportional hazard risks was tested
by using SAS (SAS Institute) to run the supremum test for the
proportional hazards assumption, which yielded P=0.488 and
was consistent with our proportional hazards assumption.
The comparison of levels of BP among treatment groups at
each visit was done using a t test for independent samples,
and a random-effects linear model fitted to systolic and
diastolic BP was used to compare BP by treatment group
during follow-up. The random-effects model included an
intercept and a slope to adjust for the within-participant
correlation among the longitudinal data. To examine the
change in systolic and diastolic BP, we included in the model
an indicator variable for time (baseline and 3, 6, 9, 12, 15, and
18 months), an interaction term for treatment by time, and
the variable treatment. Analyses were repeated with stratifi-
cation by sex, self-reported skin color,20,21 age (<50 or
≥50 years), diabetes mellitus, and obesity. Event rates were
expressed as the percentage of events by visit and at the end
of the trial, taking into account censoring of follow-up data.
The comparison of ECG estimates of LVM among the 2
treatment groups was performed by use of a t test for D
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within and between groups and for laboratory outcomes and
Pearson’s chi-square test for adverse events at the end of the
trial. Participants who abandoned the study for any reason
during follow-up were encouraged to attend an 18-month visit
for BP measurement and to obtain an ECG recording and
laboratory measurements. Statistical analyses were carried
out using SPSS version 21.0 (IBM Corp) or SAS version 9.4
using the module SAS/STAT 13.2 user’s guide (SAS Institute
Inc). Differences with P<0.05 were considered statistically
significant, without adjustment for multiplicity.
Results
Study Participants
A total of 1433 participants were enrolled in the 3-month
lifestyle-intervention phase. Of these, 730 met the criteria for
inclusion in the PREVER-Prevention trial at the conclusion of
the lifestyle phase and were randomly assigned to treatment
with chlorthalidone/amiloride (n=372) or placebo (n=358)
(Figure 1). At the 18-month visit, 312 participants in the
chlorthalidone/amiloride group and 290 participants in the
placebo group were evaluated. During follow-up, 60 partici-
pants in the chlorthalidone/amiloride group and 68 in the
placebo group discontinued their participation in the study,
mostly because of development of hypertension, the main
trial outcome. In total, 27 in the intervention group and 43 in
the placebo group did not return for the 18-month visit. All
others who developed hypertension during follow-up returned
for laboratory and ECG evaluations, although most were
receiving treatment for hypertension (a conservative bias).
Two participants in the chlorthalidone/amiloride group and 1
in the placebo group had myocardial infarction during follow-
up. There were 2 deaths, 1 in the chlorthalidone/amiloride
group from a car accident and 1 in the control group from
sudden death.
Baseline characteristics were similar between the 2 groups
(Table 1). Participants’ mean age was 50.010.4 years, 50%
were men, 55% were white, and mean systolic and diastolic
BP was 127.97.3 and 80.56.3 mm Hg, respectively.
During the trial, self-reported adherence to treatment was
similar in both groups, with an average of 84.6% stating they
had taken all or almost all of their study pills. Medication
adherence estimates based on pill counting were similar,
being on average 83.3% for the chlorthalidone/amiloride
group and 85.3% for the placebo group.
Incidence of Hypertension
The incidence of hypertension was significantly lower in the
chlorthalidone/amiloride group compared with placebo
Figure 1. Study flow diagram of the PREVER-Prevention trial,
describing selection, randomization, and follow-up process.
*Patients were concurrently screened to participate in either the
PREVER-Treatment or PREVER-Prevention trial. BP indicates blood
pressure.
Table 1. Baseline Characteristics of the PREVER-Prevention
Trial Participants
Intervention (n=372) Placebo (n=358)
Male 186 (50.0) 179 (50.1)
Age, y 5010 5011
White* 195 (52) 206 (58)
Education, years 114 114
BMI, kg/m2 295 295
Obesity (BMI ≥30) 119 (32) 110 (31)
Systolic BP, mm Hg 1287 1287
Diastolic BP, mm Hg 816 806
Potassium, mg/dL 4.60.7 4.60.6
Uric acid, mg/dL 51 51
Cholesterol, mg/dL 19337 19341
LDL-C, mg/dL 11733 12034
HDL-C, mg/dL 4713 4613
Triglycerides, mg/dL 14587 14399
Creatinine, mg/dL 0.80.2 0.80.2
Microalbuminuria, lg/24 h 6.35.9 7.06.3
Diabetes mellitus (%)† 30 (8) 29 (8)
Current smokers 28 (8) 37 (10)
Current alcoholic consumption 227 (61) 206 (58)
Data are shown as n (%) or meanSD. BMI indicates body mass index; BP, blood
pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol.
*Self-reported and categorized as white or nonwhite. Previous physician’s diagnosis, use
of antidiabetics, abnormal fasting glucose, or glycosilate hemoglobin at the baseline.
†
Previous physician’s diagnosis, use of antidiabetics, abnormal fasting glucose, or
glycosilate hemoglobin at the baseline.
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(hazard ratio 0.56, 95% CI 0.38–0.82; P=0.003), with an
apparent progressively larger difference in incident hyperten-
sion between the 2 treatment groups over time (Figure 2).
The cumulative incidence of hypertension was 11.7% in the
diuretic group compared with 19.5% in the placebo group
(P=0.004).
BP During Follow-up
The temporal pattern for mean systolic and diastolic BP is
displayed in Figure 3. Systolic BP was significantly lower in
the chlorthalidone/amiloride group compared with placebo at
every follow-up visit, and diastolic BP was significantly lower
at the 3- and 12-month visits (Table 2). Overall, the
differences were highly significant both for systolic BP
(P=0.001) and diastolic BP (P=0.04) (Figure 3). There was a
trend of greater reduction in pulse pressure in the diuretic arm
(mean 45.3, 95% CI 44.6–46.1) compared with the placebo
arm (mean 46.3, 95% CI 45.6–47.1; P=0.06).
ECG Changes in LVM
Both Sokolow-Lyon estimates identified a significant treat-
ment-related reduction in LVM in the chlorthalidone/amilor-
ide group (21.87.5 to 20.77.1 mm) but no corresponding
change in the placebo group (21.57.4 to 21.57.2 mm),
with a statistically significant (P=0.02) difference in LVM
between the 2 treatment groups at 18 months (Table 3).
Although the change in Sokolow-Lyon voltage (in mm) was
small, the difference across groups for Sokolow-Lyon voltage
Figure 2. Incidence of hypertension according to treatment
group during follow-up. HR indicates hazard ratio.
Figure 3. Blood pressure according to treatment group during follow-up.
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duration product was higher. There was a similar nonsignif-
icant trend for Cornell voltage duration product estimates of
LVM.
Microalbuminuria and Other Laboratory
Outcomes
At the end of the trial, the mean level of microalbuminuria in
the 2 treatment groups was no different (11.117.5 versus
10.616.1 lg/24 h in the diuretic and placebo groups,
respectively). Table 4 shows the baseline to last visit
variation for laboratory outcomes. The variations in low-
density lipoprotein cholesterol, potassium, and uric acid
were significantly higher in the active arm compared with
the control arm, and the variation in total cholesterol
presented a trend of significance. Overall, 5.5% of the
participants in the intervention group (n=308) and 3.3% in
the placebo group (n=305) developed diabetes mellitus
Table 2. Blood Pressure Evaluated at Each Visit Until the Development of Hypertension
Visit
No. of Patients,
Chlorthalidone+Amiloride/
Placebo
Blood Pressure
(mm Hg)
Chlorthalidone+Amiloride,
MeanSD Placebo, MeanSD P Value*
Baseline 372/358 Systolic 127.97.3 126.69.0 0.80
Diastolic 80.66.4 80.46.2 0.67
3 mo 326/316 Systolic 123.88.5 126.69.0 <0.001
Diastolic 78.66.7 79.96.9 0.01
6 mo 283/280 Systolic 123.88.2 125.88.0 0.004
Diastolic 79.06.5 79.66.8 0.36
9 mo 253/260 Systolic 123.38.4 125.68.8 0.003
Diastolic 78.46.6 79.37.4 0.13
12 mo 242/235 Systolic 122.98.6 124.78.8 0.02
Diastolic 77.86.6 79.16.7 0.03
15 mo 240/225 Systolic 122.28.5 124.59.1 0.005
Diastolic 77.56.4 78.37.4 0.19
18 mo 312/290 Systolic 123.59.9 125.610.2 0.01
Diastolic 78.07.8 78.47.8 0.48
*Analysis using a t test for independent samples at each time point.
Table 3. Left Ventricular Mass Detected by ECG Indexes According to Treatment Groups
ECG Index and Treatment Group n Baseline
18-Month
Visit
Mean Difference From Baseline
to 18-Month Visit (95% CI)
Mean Difference Between
Treatment Groups (95% CI) P Value*
Sokolow-Lyon voltage, mm†
Chlorthalidone/amiloride 251 21.87.5 20.77.1 1.04 (0.45–1.63) 1.01 (0.13–1.88) 0.02
Placebo 257 21.57.4 21.57.2 0.03 (0.61 to 0.68)
Sokolow-Lyon voltage duration product, lVms
Chlorthalidone/amiloride 246 229.0102.7 213.383.6 15.44 (5.65–25.24) 16.89 (3.11–30.62) 0.02
Placebo 253 223.098.6 224.494.4 1.43 (11.08 to 8.23)
Cornell voltage, mm†
Chlorthalidone/amiloride 252 1.250.53 1.210.50 0.04 (0.01 to 0.09) 0.47 (0.20 to 1.15) 0.17
Placebo 259 1.210.50 1.220.50 0.01 (0.05 to 0.04)
Cornell voltage duration product, lVms
Chlorthalidone/amiloride 247 129.565.5 122.856.3 6.79 (0.27 to 13.84) 9.14 (0.77 to 19.05) 0.07
Placebo 254 125.363.7 127.769.0 2.35 (9.31 to 4.60)
*Analysis using a t test for independent samples for the between-group difference.
†
1 mm=0.1 mV for patients with valid ECGs at the baseline evaluation and at visit 18.
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(P=0.18). The incidence of new albuminuria in patients free
of albuminuria (<25 lg/24 h) was similar among partici-
pants allocated to placebo (9.8%) and active treatment
(7.7%; P=0.35).
Safety
There was no statistically significant difference in overall or
individual self-reported adverse events between the 2
treatment groups (Table 5). Musculoskeletal complaints,
dizziness, and headache were the adverse events more
frequently cited by participants in both arms. Sexual dysfunc-
tion was reported by 2 (0.5%) participants allocated to diuretic
and 7 (2.0%) allocated to placebo (P=0.08). Four participants
allocated to the chlorthalidone/amiloride group discontinued
their participation in the study because of an adverse event
(Figure 1). Of these, 1 complained of itching, 2 reported
weakness and dizziness, and 1 had an abdominal rash. In the
Table 4. Laboratory Outcomes According to Treatment Groups
n
Baseline,
MeanSD
18-Month Visit,
MeanSD
Mean Difference From
18-Month Visit to
Baseline (95% CI)
Mean Difference Between
Treatment Groups (95% CI) P Value*
Glucose, mg/dL
Chlorthalidone/amiloride 332 94.922.16 97.421.6 2.50 (0.50 4.50) 1.53 (1.18 to 4.24) 0.27
Placebo 328 93.922.03 94.922.9 0.97 (0.86 to 2.80)
Glycosilate hemoglobin (%)
Chlorthalidone/amiloride 328 5.50.9 5.71.1 0.18 (0.09–0.27) 0.10 (0.022 to 0.22) 0.11
Placebo 320 5.40.8 5.50.9 0.08 (0.004 to 0.16)
Cholesterol, mg/dL
Chlorthalidone/amiloride 336 193.038.2 209.846.4 16.74 (12.70–20.78) 4.98 (0.73 to 10.69) 0.09
Placebo 329 192.041.7 203.843.3 11.77 (7.72–15.81)
LDL-C, mg/dL
Chlorthalidone/amiloride 330 117.433.9 130.343.6 12.88 (8.67–17.08) 8.10 (2.76–13.43) 0.003
Placebo 322 119.934.1 124.737.1 4.78 (1.51–8.05)
HDL-C, mg/dL
Chlorthalidone/amiloride 333 47.613.1 51.414.7 3.84 (2.73–4.95) 1.14 (0.41 to 2.68) 0.15
Placebo 328 46.312.3 49.012.6 2.70 (1.62–3.78)
Triglycerides, mg/dL
Chlorthalidone/amiloride 334 144.982.3 151.789.7 7.78 (0.15–15.41) 3.63 (15.40 to 8.14) 0. 5
Placebo 328 139.389.0 150.090.0 11.41 (2.39–20.43)
Potassium, mg/dL
Chlorthalidone/amiloride 332 4.60.7 4.40.5 0.23 (0.32 to 0.15) 0.15 (0.27 to 0.02) 0.02
Placebo 321 4.60.6 4.50.6 0.09 (0.18 to 0.003)
Creatinine, mg/dL
Chlorthalidone/amiloride 337 0.80.2 0.90.2 0.095 (0.08–0.11) 0.002 (0.05 to 0.05) 0.9
Placebo 329 0.80.2 0.90.4 0.093 (0.05–0.14)
Uric acid, mg/dL
Chlorthalidone/amiloride 336 5.31.4 5.61.4 0.34 (0.22–0.45) 0.27 (0.12–0.42) <0.001
Placebo 329 5.21.4 5.31.3 0.07 (0.03–0.17)
Microalbuminuria, lg/24 h
Chlorthalidone/amiloride 334 6.36.1 11.117.5 4.81 (3.0–6.6) 1.15 (1.38 to 3.68) 0.37
Placebo 328 6.96.3 10.616.1 3.66 (1.90–5.43)
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
*Analysis using t-test for independent samples.
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placebo group, 1 participant who complained of weakness
and dizziness abandoned the study.
Stratified Analyses
Figure 4 displays the risk of incident hypertension by baseline
categories of age, sex, skin color, BP, and presence or
absence of diabetes mellitus. The only category that yielded a
significant treatment interaction was sex, with an apparently
greater benefit of chlorthalidone/amiloride treatment for
women than men. Diabetes mellitus and obesity were more
prevalent in women compared with men, but adjustment for
these conditions did not modify the estimate substantially.
Despite the absence of a significant interaction, the risk ratios
for incident hypertension decreased in a progressive manner
with increasing decades of age: 30 to 39 years, 0.89 (95% CI
0.41–1.97); 40 to 49 years, 0.62 (95% CI 0.31–1.23); 50 to
59 years, 0.48 (95% CI 0.23–0.99); 60 to 70 years, 0.40 (95%
CI 0.15–1.04). Incidence of hypertension tended to be lower
in participants with diabetes mellitus at baseline, but the
interaction term did not meet a conventional level of
significance.
Discussion
In this randomized, double-blind, placebo-controlled, clinical
trial, treatment using low doses of a thiazide-type diuretic
combined with a potassium-sparing agent prevented the
incidence of hypertension by almost 50% in patients with
prehypertension. Moreover, the intervention appeared to be
safe and resulted in a small but nominally significant reduction
in LVM, as estimated by ECG. The incidence of new-onset
hypertension was reduced by 4% year, corresponding to a
number needed to treat of 25. During 18 months of follow-
up, BP reduction was modest and would be of insufficient
magnitude to demonstrate a significant reduction in clinical
complications over a 5- to 10-year period of follow-up, even in a
study with a very large sample size. Nonetheless, the
consequences of hypertension occur over several decades. If
maintained, effects of the size noted in our trial would likely
place many patients in a different track for increasing BP with
age, promoting lower age-related levels of BP, prevention of
CVD outcomes, and potentially avoiding of the need for high
doses of antihypertensive medications later in life.
Two previous randomized clinical trials have tested the
efficacy of drug treatment in prevention of hypertension.9,10
In the Trial of Preventing Hypertension (TROPHY) study,9
2 years of treatment with candesartan at a dose of 16 mg/
day reduced the incidence of hypertension by 66% compared
with placebo. This trial was similar to ours in its sample size
(n=772) and its use of blinding among participants, research
team, physicians, and cardiologists. The 2 trials, however, had
several important differences. First, recruitment in the
TROPHY study was restricted to participants with BP in the
upper end of the range for definition of prehypertension
(systolic BP between 130 and 139 mm Hg or diastolic BP
between 85 and 89 mm Hg),9 whereas we enrolled partici-
pants who met the generally recommended BP requirements
for diagnosis of prehypertension (systolic BP between 120
and 139 mm Hg or diastolic BP between 80 and 89 mm Hg).
Consequently, mean baseline systolic and diastolic BP values
were about 6 and 5 mm Hg higher, respectively, in the
TROPHY study. Another important difference between the 2
trials was the choice of dosage for active treatment. We chose
to use low doses of chlorthalidone and amiloride (12.5 and
2.5 mg/day, respectively), whereas the TROPHY investigators
used the standard dose of candesartan (16 mg/day). Conse-
quently, the difference in BP between the treatment groups
Table 5. Adverse Events According to Treatment Groups
During the Trial
Adverse Events*
Chlorthalidone/
Amiloride (n=372)
Placebo
(n=358) P Value†
Musculoskeletal complaints 32 (8.6) 30 (8.4) 0.9
Dizziness 33 (8.9) 25 (7.0) 0.4
Headache 19 (5.1) 27 (7.6) 0.17
Gastroesophagic
reflux symptoms
20 (5.4) 16 (4.5) 0.6
Other digestive complaints 13 (3.5) 18 (5.0) 0.3
Sleep complaints 13 (3.5) 13 (3.6) 0.9
Polyuria 16 (4.3) 8 (2.2) 0.12
Fatigue 9 (2.4) 14 (3.9) 0.2
Palpitations 6 (1.6) 10 (2.8) 0.3
Torax pain or discomfort 6 (1.6) 9 (2.5) 0.4
Eyes complains 7 (1.9) 5 (1.4) 0.6
Syncope 6 (1.6) 4 (1.1) 0.6
Sexual dysfunction
(impotence, loss of
libido or others)
2 (0.5) 7 (2.0) 0.08
Cramps 7 (1.9) 2 (0.6) 0.11
Vascular complaints 5 (1.3) 4 (1.1) 0.8
Lithiasis 2 (0.5) 7 (2.0) 0.08
Dermatological complaints 7 (1.9) 2 (0.6) 0.11
“High BP” 2 (0.5) 4 (1.1) 0.4
“Low BP” 3 (0.8) 2 (0.6) 0.7
Psychological complaints 4 (1.1) 9 (2.5) 0.14
Other adverse events 59 (15.9) 50 (14.0) 0.5
At least 1 adverse event 142 (38.2) 136 (38.1) 1.0
*Reported at least once by at least 1 patient.
†Analysis using a t test for independent samples.
BP indicates blood pressure.
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appears to have been 2 to 3 times larger in the TROPHY
study. Finally, the criteria for detection of incident hyperten-
sion during follow-up in the TROPHY study were less stringent
than generally recommended.16,17 A modeling investigation
reported that use of the TROPHY diagnostic criteria would
lead to spurious recognition of hypertension in 78% of those
studied during 18 clinic observations (the number of follow-up
visits in TROPHY).22 In contrast, reanalysis of the TROPHY
study using the criteria for diagnosis of hypertension recom-
mended in hypertension guideline documents yielded an
estimate for reduction in relative risk of incident hypertension
(0.32, 95% CI 0.24–0.42) similar to the original report.23
In the Prevention of hypertension with the angiotensin
converting enzyme inhibitor ramipril in patients with high-
normal blood pressure (PHARAO) study,10 1008 participants
with mean systolic BP between 130 and 139 mm Hg or
diastolic BP between 85 and 89 mm Hg were randomized to
3 years of open-label treatment with ramipril 5 mg daily or no
treatment. The relative risk reduction for incidence of
hypertension during follow-up was 34% (hazard ratio 0.66,
95% CI 0.53–0.81). Cough was more frequent in the ramipril
group (4.8% versus 0.4%). As was the case for the TROPHY
study, the participants in PHARAO had baseline BPs at the
upper end of the definition for prehypertension. A limitation of
the PHARAO study was the use of an open design, although
BP was measured with an automated device.
The findings of the PREVER-Prevention, TROPHY, and
PHARAO trials are consistent. Our study documents the value
of low-dose antihypertensive drug therapy for prevention of
hypertension. It also demonstrates a similar treatment-related
hypertension-prevention benefit throughout the entire range
of prehypertension BP levels. It is worth noting that our trial
and the SPRINT study24 addressed the same issue (prevention
of CVD) at opposite ends of the BP distribution. In SPRINT, an
average of 3 drugs were used to lower systolic BP from
hypertensive to optimal levels, and this yielded a very
impressive decrease in “hard” CVD outcomes. In our study
(without hard end points), we demonstrated that merely using
a half dose of the first drug used in SPRINT (chlorthalidone)
prevented the expected increase in BP to hypertensive levels
in a high proportion of patients studied.
To our knowledge, the PREVER-Prevention trial is the first
study to demonstrate a reduction in LVM following low-dose
antihypertensive drug therapy in adults with prehypertension.
In the TOHMS trial, which enrolled participants with higher
levels of BP than those used in PREVER (baseline diastolic BP
90–99 mm Hg in adults with untreated hypertension or 85–
99 mm Hg over 3 visits following withdrawal of antihyperten-
sive medication), the incidence of resting ECG abnormalities
was lesser in patients randomized to antihypertensive medica-
tion compared with placebo.19 The reduction in LVM evaluated
by echocardiogram was greater in those randomized to
Figure 4. Hazard ratio (95% CI) for hypertension in participants stratified by clinical and demographic characteristics.
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chlorthalidone (15 mg/day) compared with their counterparts
randomized to acebutolol (400 mg/day), doxazosin (2 mg/
day), amlodipine (5 mg/day), or enalapril (5 mg/day).25,26 Left
ventricular hypertrophy detected by ECG has long been
recognized as a CVD risk independent of BP levels and
hypertension, a finding that has been confirmed.27,28
Diuretics may be particularly efficacious in prehypertension
because excess consumption of sodium is likely to initiate the
pathophysiological changes that characterize this stage in the
natural history of hypertension. A common feature of isolated
populations that experience little, if any, age-related increase
in BP is their modest consumption of dietary sodium.29 The
age-related increase in BP commonly seen in most societies is
thought to represent a pathophysiological response that
facilitates renal excretion of excessively high levels of dietary
sodium consumption. Over time, high BP is thought to result
in a progressive loss of renal glomeruli and hypertrophy of the
renal arterioles, which leads to a requirement for even higher
levels of BP to facilitate natriuresis and maintenance of a
normal level of intravascular volume. This recurring patho-
physiological cycle eventually results in left ventricular and
arteriolar hypertrophy and other manifestations of subclinical
disease.30 After a prolonged period of high peripheral resistance
and increased levels of diastolic BP, the larger arterial vessels
become stiffer, with a consequent rise of systolic BP levels. This
deleterious pattern of progressive rise in BP with aging may be
aborted in the early stages of its natural history by adoption of a
diet with reduced sodium intake or by natriuresis, which can be
accomplished by administration of a diuretic at low dose. The
effect on systolic pulse pressure may lead to a decrease in
central BP. This would be another mechanism for cardiovascular
protection, reducing the increase in LVM in the group treated
with diuretics. This possibility would have to be explored in
future studies because we did not measure central BP.
Dietary change represents the optimal approach, but
achieving and maintaining a meaningful reduction in dietary
sodium through lifestyle change has proven to be very
difficult.31 While continuing to promote adoption of a healthy
diet, use of diuretics at low dose may be a more effective
means of achieving natriuresis and interrupting the dangerous
cycle of BP response to excessive consumption of sodium.
In our study, the incidence of hypertension was similar to
that described in a cohort study conducted previously in Porto
Alegre, Brazil.1 The curves for incidence of hypertension in the
2 treatment groups started to diverge at an early stage, and
the difference between the 2 treatment arms became
increasingly prominent over time. This suggests that contin-
ued administration of a low-dose diuretic could reverse the
pathophysiology that underpins typical age-related increases
in BP. Likewise, the beneficial effects on LVM that we noted
during diuretic therapy suggest that these deleterious effects
of high normal BP can also be prevented.2
The interaction between treatment and sex was unex-
pected, and it could not be readily explained by adjustment or
by differences in adherence to treatment. It may represent a
chance finding. In clinical event trials, the efficacy of
chlorthalidone treatment has not been influenced by
sex.32,33 The nonsignificant trend for greater efficacy in
patients with diabetes mellitus could have resulted from
chance or could be explained by the higher risk of developing
hypertension in those who already have diabetes mellitus,
which may be caused by loss of glomeruli and insulin-induced
sodium retention.
At the end of our study, levels of low-density lipoprotein
cholesterol and uric acid were higher in the participants
treated with the chlorthalidone/amiloride combination pill,
findings that have been noted frequently during diuretic
therapy.34 In comparison with placebo treatment, levels of
high-density lipoprotein cholesterol were also higher in the
participants treated with diuretics, whereas potassium was
slightly lower. The long-term consequences of these differ-
ences are uncertain, but even if the consequences are
deleterious, they are unlikely to exceed the benefit of
preventing incident hypertension. In our trial, participants
treated with diuretic did not experience a significant increase
in blood glucose or glycosylated hemoglobin levels. An
increased incidence of biochemical diabetes has been noted
during therapy with higher levels of chlorthalidone,32,33 but
the biological implications of this type of diabetes appears to
be benign in contrast to the high risk of CVD in persons with
obesity-related diabetes mellitus.34
Study Limitations
A limitation of our study was its sample size. Because of
resource limitations, it was not possible to enroll as many
participants as originally planned. The trial was sufficiently
large to allow for a satisfactory and highly significant test
of our main hypothesis (intervention-related prevention of
hypertension). Nonetheless, there was less satisfactory
power to assess the effect of the intervention on our
secondary outcomes. In addition, we had several secondary
outcomes, so the significant difference in LVM could have
resulted from chance due to multiple hypothesis testing.
Another limitation of our trial was the absence of out-
of-office BP measurements. Because of this, we were
unable to assess the effect of our treatment on nighttime
BP and the potential role of “white coat” and masked
hypertension.
Despite these limitations, our study had many important
strengths including use of a concealed approach to random-
ization, a double-blind design, analysis by intention to treat,
rigorous attention to quality control, blinded adjudication of
study outcomes, and a diverse sample that included
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participants from 21 academic centers distributed across 10
states in Brazil.
In conclusion, use of a fixed combination of low-dose
chlorthalidone and amiloride produced a substantial and
highly significant reduction in the incidence of hypertension
and a reduction in LVM in patients with prehypertension. The
use of low-dose diuretics in patients with prehypertension
may be an effective option to reduce the burden of
hypertension and its cardiovascular consequences.
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(Co-Principal Investigator), Leila B. Moreira. 
 
Writing Committee: Flávio D. Fuchs, Paul K. Whelton, Otávio Berwanger, Sandra C. 
Fuchs. 
 
Project Office Coordination Center: Sandra C Fuchs, Renato Bandeira de Mello, 
Francisca Mosele, Paulo R. Alencastro, Rosane Schlatter. 
 
Data Monitoring Committee: Sandra C. Fuchs, Alessandra A. Kodama, Otávio 
Berwanger.  
 
Data Safety Monitoring Committee: José Roberto Goldim, Marcia Mocelin 
Raymundo. 
 
ECG Core Laboratory: Alexandro Bordignon, Miguel Gus, Felipe C. Fuchs, Flávio D. 
Fuchs. 
 
Event Adjudication Committee: Carlos E. Poli-de-Figueiredo, Hilton Chaves Júnior, 
Paulo César V. Jardim (UFG). 
 
 
TRIAL TEAM INVESTIGATORS 
 
Hospital de Clínicas de Porto Alegre, UFRGS, RS (230 patients enrolled):  
Simone Dalla Pozza Mahmud; Andressa Alves da Silva; Caroline Nespolo de David; 
Débora Braga Rech; Flávia Ghizzoni; Guilhermo Prates Sesin; Jeniffer Peretti; Leticia 
Rafaelli; Maria Eduarda Claus; Marilze Alves Quessada; Querino Haesbaert; Rafael V. 
Picon; Ruchelli França de Lima; Sinara L. Rossato; Sonia Alencastro; Suzane 
Schreiner. 
 
Hospital Universitário Júlio Müller, MT (75): Jeniffer L. D. Soares Silva, Marcus 
Antonio Godoy, Samantha Dutra Fernandes.  
 
Faculdade de Medicina São José do Rio Preto, SP (46): Andressa da Silva Aguera, 
Camila Carla Gaglianone, Carolina Neves Consenso Sacomani, Leticia Aparecida 
Barufi.  
 
Faculdade de Medicina e Hospital São Lucas, PUCRS, RS (37): Carmen Silvana 
Araújo Oliveira, Domingos d’Ávila, Giovani Gadonski, Leonardo Viliano Kroth, 
Magna Cristina Traesel, Renata Souza da Silva. 
 
Hospital Universitário Walter Cantídio, CE (28): Deborah Cabral, Denize Cardoso 
Matias Vale, Jeruza Mara de Oliveira Lima, Márcia Maria Carneiro.  
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Faculdade de Ciências Farmacêuticas, USP Ribeirão Preto, SP (28): Ana Lucia 
Tosta Teixeira, Analuiza Souza Costa, Carolina Almeida Martinelli, Cristiane Silveira 
Guidi, João Rodrigues Lima Junior, Maria Aparecida Soares Viana, Poliana Carina 
Paolini. 
 
Instituto de Cardiologia, RS (26): Ana Paula Vanz, Andressa Silveira de Oliveira, 
Ellen Greyce Sodré Ramos, Humberto Andrez Vaz, Liliane Apprato de Souza, Simone 
Sieben Mota, Vanessa Sieben Mota. 
 
Hospital Universitário Universidade Federal do Maranhão, MA (24): Liendne 
Penha Abreu, Ludmila B. Palhano Portela, Maria Jaqueline Silva Ribeiro, Marinilde 
Teles, Paula Nascimento dos Santos, Renata Melo de Assis.  
 
Universidade Federal de Pernambuco, PE (20): Daiane Santana da Silva, Daniele 
Calaça de Oliveira, Erika Maria Santos da Silva, Manuela Costa de Medeiro, Maria da 
Conceição Chaves de Lemos, Rinaldo Pereira de Almeida, Simone Teixeira Nogueira 
Lima, Thatiana Maria Cavalcante Alves de Souza, Weslley Carlos de Souza.  
 
Universidade Federal de Pelotas, RS (19): Angélica Bandeira Afonso Moutinho, 
Camila Torres Fonseca, Felipe da Silva Paulitsch, Marcos Klering Mesquita, Silvana 
Paiva Orlandi.  
 
Universidade do Estado do Rio de Janeiro, RJ (17): Flávia Lopes Fonseca, Maria 
Eliane Campos Magalhães, Rafael Almeida Faria, Simone Offrede;  
 
Instituto de Medicina Integral Prof Fernando Figueira, PE (16): Camila Patrício 
Miranda, Rosiane Victor Alves. 
 
Hospital das Clínicas da Universidade Federal de Minas Gerais, MG (14): 
Fernanda Soares Correa de Lima e Silva, Maria Fernanda Freitas de Figueiredo, 
Matheus de Paula Alves, Renan Oliveira, Vanilda Borges;  
 
Hospital das Clínicas de Goiânia, GO (12): Ana Luiza Lima Sousa, Andréa Cristina 
de Sousa, Luciana da Ressureição Santos, Naiana Borges Perillo, Taysa Cristina dos 
Santos, Rafaela Bernardes Rodrigues, Thiago de Souza Veiga Jardim, Ymara Cássia 
Luciana Araújo.  
 
Instituto do Coração, Universidade de São Paulo, SP (12): Marília Almeida, 
Meyrielli Vieira Thais Reis de Leão, Thiago Midlej Brito. 
 
Faculdade de Medicina de Botucatu, SP (12): Mariana Vulcano Neres;  
 
Hospital do Coração de Alagoas, AL (07): Alana Costa Machado Gomes, Anita 
Machado Gomes Schettino, Annelise Machado Gomes de Paiva, Glauber Schettino da 
Silva, Maria Inês Costa Machado Gomes, Pedro Victor da Rocha Noé;  
 
Hospital Anis Rassi, GO (04): Amanda da Rocha Oliveira, Diane Gonçalves, Ligia 
Socorro Araujo;  
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Hospital Universitário PROCAPE, PE (04): Adriano Assis Mendes, Bento José 
Bezerra Neto, Daniela Lopes da Silva Martins, Eveline Lustosa Pires Almeida. 
 
Hospital Universitário Antônio Pedro, UFF, RJ (03): Beni Olej, Aline Sterque 
Villacorta, Clarissa Assumpção, Nínive da Silva Pinto;  
 
Faculdade de Medicina de Ribeirão Preto, USP Ribeirão Preto, SP (03):Alessandra 
Marino Bárbaro, Pedro Vellosa Schwartzman;  
 
Research Institute, Hospital do Coração, SP: Alessandra A Kodama. 
 
STUDY MEDICINE MANUFACTURER: Laboratório de Produção e Análise de 
Medicamentos, Universidade do Vale do Itajaí. 
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